Telix Completes Acquisition of ImaginAb, Expanding Theranostic Pipeline

Telix Pharmaceuticals has successfully completed its acquisition of ImaginAb, a leader in antibody engineering, strengthening its capabilities in radiopharmaceutical development. This acquisition brings a portfolio of next-generation therapeutic candidates targeting validated cancer markers like DLL3 and integrin αvβ6, along with a cutting-edge biologics platform for precision oncology. By integrating ImaginAb’s expertise in small engineered antibodies with Telix’s radiopharmaceutical advancements, the company aims to accelerate the development of innovative cancer treatments with highly specific tumor-targeting capabilities.

The acquisition also expands Telix’s U.S. operations, adding a state-of-the-art research facility in Los Angeles and enhancing its existing infrastructure in radiochemistry, isotope production, and bioconjugation. With ImaginAb’s team joining Telix’s early development unit, the company is poised to drive new advancements in protein engineering and preclinical research. “This acquisition creates new opportunities for Telix to develop precision medicine beyond our current pipeline,” said Michael Wheatcroft, Chief Scientist at Telix. Dr. Anna M. Wu, Co-Founder of ImaginAb, added that the team is eager to contribute to Telix’s vision of optimizing radiopharmaceutical therapies.